Effects of tissue handling on rna integrity and microarray measurements from resected breast cancers

Journal of the National Cancer Institute

Volumn 103, Issue 24, 2010, Pages 1871-1883

  Hatzis, Christos ^b   Sun, Hongxia ^a   Yao, Hui ^a   Hubbard, Rebekah E ^a   Meric Bernstam, Funda ^a   Babiera, Gildy V ^a   Wu, Yun ^a   Pusztai, Lajos ^a   Symmans, W Fraser ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Nuvera Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER TISSUE; CLINICAL ARTICLE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; PRIMARY TUMOR; PRIORITY JOURNAL; ROOM TEMPERATURE; TISSUE MICROARRAY; BIOPSY; BREAST TUMOR; CRYOPRESERVATION; FEMALE; FREEZE DRYING; GENE EXPRESSION REGULATION; GENETICS; LABORATORY DIAGNOSIS; LUNG CARCINOMA; MASTECTOMY; METABOLISM; METHODOLOGY; MICROARRAY ANALYSIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, SQUAMOUS CELL; CRYOPRESERVATION; FEMALE; FREEZE DRYING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MASTECTOMY; MICROARRAY ANALYSIS; MIDDLE AGED; RNA, NEOPLASM; SPECIMEN HANDLING; TIME FACTORS;

EID: 84862838130     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr438     Document Type: Article

References (46)

1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874. (Pubitemid 32878711)
2. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239-1246. (Pubitemid 46640570)
3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826. (Pubitemid 40051905)
4. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-5685. (Pubitemid 41170290)
5. Dobbe E, Gurney K, Kiekow S, et al. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. Am J Health Syst Pharm. 2008;65(1):23-28.
6. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
7. Ross JS, Hatzis C, Symmans WF, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13(5):477-493. (Pubitemid 351872866)
8. Abdullah-Sayani A, Bueno-de-Mesquita JM, van de Vijver MJ. Technology Insight: tuning into the genetic orchestra using microarrays-limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol. 2006;3(9):501-516. (Pubitemid 44340366)
9. Ioannidis JP. Is molecular profiling ready for use in clinical decision making? Oncologist. 2007;12(3):301-311. (Pubitemid 46556796)
10. Sparano JA, Solin LJ. Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making. J Clin Oncol. 2010;28(10):1625-1627.
11. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006;24(9):1151-1161. (Pubitemid 44359727)
12. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol. 2006;24(9):1115-1122. (Pubitemid 44359723)
13. Jewell SD, Srinivasan M, McCart LM, et al. Analysis of the molecular quality of human tissues: an experience from the Cooperative Human Tissue Network. Am J Clin Pathol. 2002;118(5):733-741. (Pubitemid 37046318)
14. Dash A, Maine IP, Varambally S, et al. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol. 2002;161(5):1743-1748. (Pubitemid 35265532)
15. Erickson HS, Josephson JW, Vira M, et al. Influence of hypoxia induced by minimally invasive prostatectomy on gene expression: implications for biomarker analysis. Am J Transl Res. 2010;2(3):210-222.
16. Huang J, Qi R, Quackenbush J, et al. Effects of ischemia on gene expression. J Surg Res. 2001;99(2):222-227. (Pubitemid 32703440)
17. Spruessel A, Steimann G, Jung M, et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques. 2004;36(6):1030-1037. (Pubitemid 38747367)
18. Febbo PG, Kantoff PW. Noise and bias in microarray analysis of tumor specimens. J Clin Oncol. 2006;24(23):3719-3721. (Pubitemid 46622310)
19. Lin DW, Coleman IM, Hawley S, et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol. 2006;24(23):3763-3770. (Pubitemid 46622315)
20. De Cecco L, Musella V, Veneroni S, et al. Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer. 2009;9:409. doi:10.1186/1471-2407-9-409
21. Mutter GL, Zahrieh D, Liu C, et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics. 2004;5(1):88.
22. Micke P, Ohshima M, Tahmasebpoor S, et al. Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. Lab Invest. 2006;86(2):202-211. (Pubitemid 43117599)
23. Bakay M, Chen YW, Borup R, et al. Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics. 2002;3:4. doi:10.1186/1471-2105-3-4 (Pubitemid 38751200)
24. Barry WT, Kernagis DN, Dressman HK, et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol. 2010;28(13):2198-2206.
25. Blackhall FH, Pintilie M, Wigle DA, et al. Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia. 2004;6(6):761-767. (Pubitemid 40041494)
26. Schoor O, Weinschenk T, Hennenlotter J, et al. Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques. 2003;35(6):1192-1196; 1198-1201.
27. TABPW Group. Expression profiling-best practices for data generation and interpretation in clinical trials. Nat Rev Genet. 2004;5(3):229-237.
28. Leyland-Jones BR, Ambrosone CB, Bartlett J, et al. Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol. 2008;26(34):5638-5644.
29. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3. doi:10.1186/1471-2199-7-3
30. Greene FL, Page DL, Fleming ID, et al. Manual for Staging Cancer. 6th ed. New York: Springer-Verlag; 2002.
31. Affymetrix. GeneChip Expression Analysis: Technical Manual. Santa Clara, CA: Affymetrix; 2004.
32. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
33. Symmans WF, Hatzis C, Sotiriou C, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28(27):4111-4119.
34. Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305(18):1873-1881.
35. Jackson JE, Mudholkar GS. Control procedures for residuals associated with principal components analysis. Technometrics. 1979;21(3):341-349. (Pubitemid 9472204)
36. Affymetrix. Gene Chip Expression Analysis: Data Analysis Fundamentals. Santa Clara, CA: Affymetrix; 2004.
37. Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009;27(19):3185-3191.
38. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4):262-272. (Pubitemid 43264710)
39. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
40. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355(6):560-569. (Pubitemid 44200649)
41. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-Plus. New York, NY: Springer-Verlag; 2000.
42. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/ Hierarchical Models. New York, NY: Cambridge University Press; 2007.
43. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
44. Bates DM, Maechler M. lme4: Linear Mixed-Effects Models Using S4 Classes. R package version 0.999375-32. 2009. http://CRAN.R-project.org/package=lme4.
45. Loi S, Symmans WF, Bartlett JM, et al. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types [published online ahead of print June 20, 2011] Lancet Oncol. 2011. doi:10.1016/S1470-2045(11)70117-6
46. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med. 2006;27(2-3):126-139.